



UNIVERSITY OF
CAMBRIDGE

BIO4
CAMPUS



Bridging Borders: Advancing Translational Oncology Research through AI

EuroCC4SEE Workshop, May 20th, 2025

Stefan Milosevic, University of Cambridge |
BIO4 Campus Belgrade



Why Borders Still Exist in Cancer Research

Cancer doesn't care about borders. So why do our research systems?

Translational oncology today is fragmented:



From Bench to Bedside: The Translational Oncology Challenge

01

Translational oncology means converting lab breakthroughs into clinical treatments

02


But there's a "data chasm" between discovery and real-world deployment

03

Genomics \neq Clinical trials \neq Imaging \neq Real-world outcomes


04

Solution: What's missing? A common computational language across modalities and institutions



AI as the Bridge: Not a Silver Bullet, but a Shared Protocol

AI helps navigate complexity, **not replace** clinicians or researchers





scMultiGraph: single-cell Multiomic Modelling with Message Passing Graph Neural Networks

Problem?



- Genomics data are often analyzed in silos-chromatin accessibility and gene expression separately

Result:

- Amongst the first of the graph neural network models to **connect multiomic data** at single-cell resolution
- Achieved high predictive accuracy across a set of variable genes

Broader implication:

- Modelling regulatory gene networks dynamically- essential for understanding therapy response and disease mechanisms



From *scMultiGraph* to Real-World AI Barriers

○ STANDARDIZATION

Lack of **standardized architectures** for multiomic data integration

○ ACCESS

Limited access to **high-quality, diverse training data**

○ CLINICAL VALIDATION

Disconnection between **academic modelling** and **clinical validation**

My thesis clarified:

Next... **How do we deploy this in real-world cancer settings-ethically and scale it properly?**

***BRain-MOD** (Brain Response and Infiltration Modeling through Omics and Dynamics): Digital Twin Modeling of Glioma Evolution and Therapy Response*



BIO4 Campus will be home to a multidisciplinary set of tenants, creating an ideal ecosystem for innovation

9 Institutes

7 Faculties

Convention Centre

Accommodation

Startup park

Private R&D Departments



Oncology Across BIO4 - A Shared Domain

Oncology is not a separate pillar at BIO4; rather, it's a cross-cutting domain worked on across multiple tenant institutions

Key Projects & BIO4 Tenants

- **IMGGE**
DNA repair and genome stability (BRCA2-related)
Targeting vulnerabilities in HR-deficient cancers
- **Faculty of Medicine + IORS (Institute for Oncology and Radiology of Serbia)**
Biomarker discovery in rectal cancer
Personalized treatment pathways through EU collaboration
- **IMI**
Anti-inflammatory diets during breast cancer therapy
Linking nutrition, clinical outcomes, and ML models
- **IBISS + Faculty of Chemistry**
Novel hybrid anticancer compounds
Designed to reduce toxicity and overcome drug resistance

BIO4 enables these projects to intersect through AI and infrastructure, without creating artificial silos

2025 ASCO[®] ANNUAL MEETING

ASCO 2025 - Serbia's Presence in Oncology & AI

I will represent
BIO4 Campus at
this year's ASCO
Annual Meeting
2025

Oncology projects
from our BIO4
tenants

AI use cases in
immunology, rare
disease
modelling, and
drug delivery

Objective:
Position Serbia
not just as a
consumer of
oncology AI, but
as a co-developer
and global partner



Final Message - Research Without Borders

We don't need more data. We need more connection.

Translational oncology requires:

- Shared purpose across institutions
- AI tools that are co-designed for use-case purposes, not copy-pasted
- Platforms that respect institutional differences but enable common learning

Let's move from bordered science to bridged ecosystems